DISSOLUTION ENHANCEMENT OF DIACEREIN USING WATER SOLUBLE CARRIER BY SOLID DISPERSION TECHNOLOGY
Abstract
Diacerein is generally used in the treatment of Osteoarthritis , this drug comes under the class anthraquinone. The drug is practically insoluble in water and exhibits exceptionally slow and intrinsic dissolution rate with poor bioavailability. In the present study, diacerein and β-cyclodextrin (β-CD) solid dispersions were prepared with a view to study the effect and influence of β-CD on the solubility and dissolution rate of this poorly aqueous soluble drug. Phase solubility profile revealed that the solubility of diacerein was significantly increased in the presence of β-CD and indicating the possible 1:1 stoichiometric inclusion complex with a stability constant of 339.66 M-1. Effect of variable such as drug: Carrier ratios were studied. Physical characterization of the solid dispersion was characterized by Fourier transform infrared spectroscopy (FT-IR), Differential scanning calorimetry (DSC) and X-ray diffraction studies (XRD). These studies revealed that a distinct loss of drug crystallinity in the solid dispersion is ostensibly accounting for enhancement of dissolution rate in distilled water containing 0.1% Tween 80. The scanning electron microscopy (SEM) study revealed that all the binary systems appeared as agglomerates and exhibiting the presence of a homogenous solid phase which could also be responsible for the enhanced dissolution rate in comparison with the pure drug. The drug release from the prepared solid dispersion exhibited a first order kinetics. Solid dispersion of diacerein showed a 7.66 times fold increase in dissolution rate over the pure drug.
Downloads
References
2. Leuner C and Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm, 2000, 50, 47-60.
3. Lipinski C. Poor aqueous solubility – An industry wide problem in drug delivery. Am. Pharm. Rev, 2002, 5, 82-85.
4. Hu J, Johnson K.P, Williams R.O. Rapid dissolving high potency danazol powders produced by spray freezing into liquid process. Int. J. Pharm, 2004, 271, 145-154.
5. Aungst, B.J, Novel formulation strategies for improving oral bioavailability of drugs poor membrane permeation in presystemic metabolism. J. Pharm Sci, 1993, 82, 879-987.
6. Hye J.A, Kyong M.K, Choi J.S, Kim C.K. Effects of cyclodextrin derivatives on bioavailability of ketoprofen. Drug Dev. Ind. Pharm, 1997, 23(3), 331-335.
7. Maurya SD, Arya RKK, Rajpal G, Dhakar RC, Self-micro emulsifying drug delivery systems (SMEDDS): a review on physico-chemical and biopharmaceutical aspects, Journal of Drug Delivery and Therapeutics, 2017; 7(3):55-65
8. Shah DP, Patel B, Shah C, Nanosuspension technology: A innovative slant for drug delivery system and permeability enhancer for poorly water soluble drugs, Journal of Drug Delivery and Therapeutics, 2015; 5(1):10-23
9. Law S.L, Lo W.Y, Lin F.M, Chaing C.H. Dissolution and absorption of nifedipine in poly ethylene glycol solid dispersion containing phosphatidyl choline. Int. J. Pharm, 1992, 84, 161-166.
10. Corrigan O.I. Mechanisms of dissolution of fast release solid dispersions. Drug Dev. Ind. Pharm, 1985, 11, 697-724.
11. Craig D.Q.M. Poly ethylene glycols and drug release. Drug Dev. Ind. Pharm, 1990, 16, 2501-2526.
12. Dalvi PB, Gerange AB, Ingale PR, Solid dispersion: strategy to enhance solubility, Journal of Drug Delivery and Therapeutics, 2015; 5(2):20-28
13. Ford J.L. The current status of solid dispersions. Pharm. Acta Helv, 1986, 61, 69-88.
14. Madhusudhan B, Rambhav D, Gudsoorkar V.R, Shete J.S, Apte S.S. Studies on sulphamethoxazole solid dispersions and their tablets. Indian J. Pharm. Sci, 2002, 64(3), 233-238.
15. Delahaye N., Duclos R., Saiter J.M, Varnier S., Characterization of solid dispersions phase transitions using a new optical thermal analyzer. Drug Dev. Ind. Pharm., 1997, 23(3), 293-303.
16. Bhirud YD, Phalak HM, Advances in solid dispersion technology and its applications in the development of solid dosage forms, Journal of Drug Delivery and Therapeutics, 2016; 6(6):40-47
17. Lachman L., Liberman H.A. Kanig J.L. eds: The Theory and Practice of Industrial Pharmacy, 3rd Edn, Varghese Lea Febiger, Philadelphia, PA, 1987. P. 317-318.
18. Aulton M.E, amd Wells T.I., Pharmaceutics: The Science of Dosage Form Design. Churchill Livingstone, London, England, 1988, 247-248.
19. Mehta S, Joseph NM, Feleke F, Palani S, Improving solubility of BCS class II drugs using solid dispersion: a review, Journal of Drug Delivery and Therapeutics, 2014; 4(3):7-13
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.